BC
Broadfin Capital Portfolio holdings
AUM
$403M
1-Year Return
74.97%
This Quarter Return
-9.91%
1 Year Return
+74.97%
3 Year Return
+245.63%
5 Year Return
+336.04%
10 Year Return
–
AUM
$485M
AUM Growth
-$72.1M
(-13%)
Cap. Flow
+$58.2M
Cap. Flow
% of AUM
11.99%
Top 10 Holdings %
Top 10 Hldgs %
53.68%
Holding
58
New
11
Increased
13
Reduced
15
Closed
9
Top Buys
| 1 |
NVRO
NEVRO CORP.
NVRO
|
$29M |
| 2 |
TSRO
TESARO, Inc.
TSRO
|
$25.1M |
| 3 |
DexCom
DXCM
|
$18.7M |
| 4 |
Aclaris Therapeutics
ACRS
|
$13.9M |
| 5 |
Incyte
INCY
|
$11.7M |
Top Sells
| 1 |
CORI
Corium International, Inc.
CORI
|
$22.5M |
| 2 |
Tandem Diabetes Care
TNDM
|
$18.4M |
| 3 |
Pacific Biosciences
PACB
|
$13.5M |
| 4 |
Xenon Pharmaceuticals
XENE
|
$11.8M |
| 5 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
$8.04M |
Sector Composition
| 1 | Healthcare | 87.48% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
SCYNEXIS
SCYX
$37.3M
| – | – |
-188,590
| Closed | -$2.26M |
|
52
SPDR S&P 500 ETF Trust
SPY
$660B
| – | – |
0
| – | – |
|
53
SPDR S&P Biotech ETF
XBI
$5.39B
| – | – |
0
| – | – |
|
|
54
Xenon Pharmaceuticals
XENE
$3.02B
| – | – |
-895,553
| Closed | -$11.8M |
|
|
HZNP
55
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| – | – |
-410,532
| Closed | -$8.04M |
|
|
CORI
56
DELISTED
Corium International, Inc.
CORI
| – | – |
-2,368,557
| Closed | -$22.5M |
|
|
OMED
57
DELISTED
OncoMed Pharmaceuticals, Inc.
OMED
| – | – |
-200,000
| Closed | -$424K |
|